Day: January 5, 2024

New offering supports management and reporting capabilities at the enterprise scale Jacksonville, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) —Everything Blockchain Inc., (OTCMKTS: EBZT), a technology company that is blending blockchain, DBMS and Zero Trust to deliver disruptive new ways to store, manage and protect data, has launched EB Control Enterprise. Expanding upon the celebrated EB Control platform, EB Control Enterprise will feature an enhanced centralized management portal, empowering companies to perform comprehensive enterprise management and reporting on a larger scale. EB Control Enterprise now also plugs seamlessly into enterprise IT workflows such as Active Directory ADFS and adds support for FIDO 2 and SAML. In an era defined by the diligent pursuit of data security and privacy, security professionals are constantly...

The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion. Tevogen Bio is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.New York, NY, Jan. 05, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Inc (“Tevogen Bio”), an advanced-stage specialty immunotherapy biotech pioneer and Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that the Securities and Exchange Commission (“SEC”) has declared effective the registration statement on Form S-4 (the “Registration Statement”) filed by Semper Paratus in connection...

MANCHESTER, N.H., Jan. 05, 2024 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro”) (Nasdaq: ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced that the Company will present at Needham’s 26th Annual Growth Conference on Friday, January 19, 2024, which is a designated day for virtual presentations and meetings. Vineet Nargolwala, President and Chief Executive Officer, and Derek D’Antilio, Chief Financial Officer, are scheduled to participate in a fireside chat at 12:45 PM EDT. A live and archived webcast of the fireside chat will be available on the Investor Relations page of the Company’s website at www.allegromicro.com. About Allegro MicroSystemsAllegro MicroSystems is a leading global designer, developer, fabless manufacturer and marketer...

PLEASANTON, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) — Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leader in digital transformation solutions including managed services, cloud enablement, cybersecurity, data analytics, and AI data processing for the healthcare and life sciences industries, announced that it will sponsoring and participating at the 2024 MUSE Executive Institute, being held Jan 7th-9th, 2024 at The Resort at Pelican Hill in Newport Beach, California. “We are excited to participate and sponsor this prestigious event,” said Lena Kannappan, Co-founder, Head of Business and Strategic Partnerships for Healthcare Triangle. “The event’s theme ‘Solving Workforce Challenges’, encompasses staffing, productivity, and AI integration, for which Healthcare Triangle specializes and...

Findings published in the American Heart Journal show higher clinical diagnostic yield and lower odds of retesting with Zio long-term continuous monitoring service (LTCM) compared to other LTCM and ambulatory cardiac monitoring (ACM) products LTCM was associated with lower incremental health care utilization and costSAN FRANCISCO, Jan. 05, 2024 (GLOBE NEWSWIRE) — (NASDAQ:IRTC) today announced that the results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events (CAMELOT) study have been published in the American Heart Journal (AHJ). The peer-reviewed manuscript, titled “Comparative Effectiveness and Healthcare Utilization for Ambulatory Cardiac Monitoring (ACM) Strategies in Medicare Beneficiaries,” reveals that the Zio long-term continuous monitoring service (LTCM), which features up to 14 continuous...

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in PIVOT-PO Phase 3 trial for tebipenem HBr in cUTI patients. Entitled to receive $95 million in development milestones, payable over two years, as part of the GSK license agreement Updated preliminary cash balance and cash runway guidance into late 2025 CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset, clinical-stage, biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need, today provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024. “We look forward to another productive...

CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of $150,000,000, before deducting underwriting discounts and expenses payable by Catalyst. Catalyst has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts. The offering is expected to close on or about January 9, 2024, subject to customary closing conditions. All of the shares in the offering are being sold by Catalyst. BofA Securities, Citigroup, Piper Sandler & Co., Cantor,...

Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in Q2 2024 and announce initial clinical data in mid-2024 Phase 1 clinical trial of XMT-2056, Immunosynthen HER2 ADC, restarting; plan to advance dose escalation in 2024 Expect capital resources will support current operating plan commitments into 2026 Company to webcast presentation from 42nd Annual J.P. Morgan Healthcare Conference at 2:15 p.m. Eastern Time (ET)/11:15 a.m. Pacific Time (PT) on January 11, 2024CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical...